Headlines
Bayer eyes launch of menopause relief, heart drugs this year
Published by Global Banking & Finance Review®
Posted on April 1, 2025
1 min readLast updated: January 24, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on April 1, 2025
1 min readLast updated: January 24, 2026
Bayer is set to launch Beyonttra for heart failure and elinzanetant for menopause relief in 2023, each with potential sales exceeding $1 billion.
(Reuters) -Bayer said on Tuesday it was preparing market launches this year of two new drugs that could each have annual peak sales of at least $1 billion, as it seeks to strengthen its pharmaceuticals business amid a high debt burden.
In a statement, the German maker of drugs and agricultural supplies said it would bring Beyonttra, also known as acoramidis, to market to treat a condition that results in heart failure.
In "late summer" this year, it was eyeing the launch of menopause relief drug elinzanetant to ease hot flashes, it added.
It said both had blockbuster potential, an industry term for potential peak annual sales of at least $1 billion.
(Reporting by Ludwig Burger and Patricia WeissEditing by Madeline Chambers)
The article discusses Bayer's planned launch of two new drugs in 2023, targeting heart failure and menopause relief.
Bayer is launching Beyonttra for heart failure and elinzanetant for menopause relief.
Both drugs have the potential to achieve annual sales of at least $1 billion.
Explore more articles in the Headlines category
